Dr. Vincent Chen, MD
Cardiology (Cardiovascular Disease Physician)
At a glance
- In the NPI registry since
- 2015
Licensed in Illinois since 2021, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
OH license 35.145518 -
Internal Medicine Physician
IL license 036.158929 (first issued 2021; active) · IL license 125074931 · OH license 35.145518
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Cleveland, OH | 13 |
| Atorvastatin Calcium Other prescribers in Cleveland, OH | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 20 payments worth $2,014 in total to this clinician.
| Boston Scientific Corporation | $1,308 |
|---|---|
| Edwards Lifesciences Corporation | $211 |
| Medtronic, Inc. | $183 |
| Shockwave Medical, Inc | $151 |
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $40.94 |
| Teleflex LLC | $33.56 |
| Argon Medical Devices, Inc. | $24.42 |
| Recor Medical Inc | $24.21 |
| Food and Beverage | $1,101 |
|---|---|
| Travel and Lodging | $731 |
| Education | $183 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boston Scientific Corporation May 30, 2025 | Travel and Lodging General - Therapies · General - Therapies_IC · travel to Boston, MA · in-kind | $252 |
| Boston Scientific Corporation May 30, 2025 | Travel and Lodging General - Therapies · General - Therapies_IC · travel to Boston, MA · in-kind | $243 |
| Medtronic, Inc. Feb 26, 2025 | Education RESOLUTE ONYX · Stents · in-kind | $183 |
| Boston Scientific Corporation May 31, 2025 | Travel and Lodging General - Therapies · General - Therapies_IC · travel to Boston, MA · in-kind | $170 |
| Boston Scientific Corporation Jul 24, 2025 | Travel and Lodging General - Vascular Access · General - Vascular Access_IC · travel to Boston, MA | $65.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 1 companies. The companies reported $3,036 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Eli Lilly and Company · Completed · NCT05882045 - A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929066 - A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929079 - A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Eli Lilly and Company · Terminated · NCT05592275 - A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Eli Lilly and Company · Completed · NCT05931367 - A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05936151
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.